Skip to main content

Table 2 PTTG1IP and securin in breast carcinoma

From: PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival

 

All subtypes

TNBC

n=401

n=96

Neg PTTG1IP (%)

High securin (%)

Cytoplasmic securin (%)

Neg PTTG1IP (%)

High securin (%)

Cytoplasmic securin (%)

All patients

25.7

39.5

17.5

57.3

82.6

79.2

Nodal status

 Node -

22.3

43.4

7.9

38.5

36.5

47.9

 Node +

27.1

63.1

9.2

15.6

21.9

30.2

Tumour size

 <2cm

18.2

19.4

4.7

25.0

21.9

29.2

 ≥2cm

28.6

35.6

13.1

29.2

34.4

47.9

Histological grade

 I

8.8

11.5

1.7

0

0

0

 II

21.5

26.1

14.1

0

0

0

 III

49.4

64.2

25.2

100

100

100

Intrinsic classification

 Luminal

11.5

29.6

3.2

   

 HER2-amplified

25.5

40.7

8.7

   

 Triple-negative

63.8

62.7

11.9

   
  1. The table summarizes for each patient group the fractions (%) of cases with immunoexpression patterns indicating aggressive course of disease (negative PTTG1IP, high securin expressiona and cytoplasmic securin expression). The results are presented separately for all subtypes of breast carcinomas (n=401) and for TNBCs (n=96) and in subgroups divided according to the established prognosticators of breast cancer
  2. aHigh securin expression: securin-positivity observed in ≥10% of cancer cells
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us